Allianz Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.57M | Sell |
8,000
-2,000
| -20% | -$933K | ﹤0.01% | 1322 |
|
|
2025
Q4 | $4.53M | Sell |
10,000
-200
| -2% | -$86.2K | ﹤0.01% | 1178 |
|
|
2025
Q3 | $3.99M | Sell |
10,200
-900
| -8% | -$376K | ﹤0.01% | 1209 |
|
|
2025
Q2 | $4.94M | Buy |
11,100
+1,200
| +12% | +$553K | 0.01% | 1119 |
|
|
2025
Q1 | $4.8M | Buy |
9,900
+6,900
| +230% | +$3.22M | 0.01% | 1136 |
|
|
2024
Q4 | $1.21M | Sell |
3,000
-300
| -9% | -$139K | ﹤0.01% | 1587 |
|
|
2024
Q3 | $1.53M | Buy |
3,300
+300
| +10% | +$144K | ﹤0.01% | 1504 |
|
|
2024
Q2 | $1.41M | Sell |
3,000
-1,500
| -33% | -$651K | ﹤0.01% | 1446 |
|
|
2024
Q1 | $1.88M | Sell |
4,500
-7,400
| -62% | -$3.13M | ﹤0.01% | 1199 |
|
|
2023
Q4 | $4.84M | Sell |
11,900
-7,800
| -40% | -$2.88M | 0.01% | 927 |
|
|
2023
Q3 | $6.85M | Buy |
19,700
+10,200
| +107% | +$3.57M | 0.01% | 860 |
|
|
2023
Q2 | $3.34M | Buy |
9,500
+1,600
| +20% | +$539K | 0.01% | 1039 |
|
|
2023
Q1 | $2.49M | Buy |
7,900
+3,500
| +80% | +$1.05M | ﹤0.01% | 1284 |
|
|
2022
Q4 | $1.27M | Buy |
4,400
+2,300
| +110% | +$701K | ﹤0.01% | 1433 |
|
|
2022
Q3 | $608K | Buy |
2,100
+1,000
| +91% | +$288K | ﹤0.01% | 1503 |
|
|
2022
Q2 | $310K | Buy |
1,100
+300
| +38% | +$80.3K | ﹤0.01% | 2008 |
|
|
2022
Q1 | $209K | Buy |
+800
| New | +$190K | ﹤0.01% | 2275 |
|
|
2021
Q4 | – | Sell |
-4,200
| Closed | -$762K | – | 2708 |
|
|
2021
Q3 | $762K | Buy |
4,200
+400
| +11% | +$78.1K | ﹤0.01% | 2056 |
|
|
2021
Q2 | $766K | Buy |
+3,800
| New | +$795K | ﹤0.01% | 1856 |
|
|
2020
Q3 | – | Sell |
-5,200
| Closed | -$1.51M | – | 2417 |
|
|
2020
Q2 | $1.51M | Sell |
5,200
-9,300
| -64% | -$2.52M | ﹤0.01% | 1716 |
|
|
2020
Q1 | $3.45M | Sell |
14,500
-6,700
| -32% | -$1.54M | ﹤0.01% | 1319 |
|
|
2019
Q4 | $4.64M | Sell |
21,200
-2,000
| -9% | -$405K | ﹤0.01% | 1512 |
|
|
2019
Q3 | $3.93M | Buy |
23,200
+3,000
| +15% | +$531K | ﹤0.01% | 1564 |
|
|
2019
Q2 | $3.7M | Buy |
20,200
+11,700
| +138% | +$2.05M | ﹤0.01% | 1642 |
|
|
2019
Q1 | $1.56M | Buy |
8,500
+6,100
| +254% | +$1.13M | ﹤0.01% | 1929 |
|
|
2018
Q4 | $398K | Sell |
2,400
-1,500
| -38% | -$260K | ﹤0.01% | 2335 |
|
|
2018
Q3 | $752K | Hold |
3,900
| – | – | ﹤0.01% | 2302 |
|
|
2018
Q2 | $663K | Hold |
3,900
| – | – | ﹤0.01% | 2328 |
|
|
2018
Q1 | $636K | Sell |
3,900
-39,200
| -91% | -$6.4M | ﹤0.01% | 2333 |
|
|
2017
Q4 | $6.46M | Buy |
43,100
+1,000
| +2% | +$148K | 0.01% | 1511 |
|
|
2017
Q3 | $6.4M | Buy |
42,100
+9,900
| +31% | +$1.49M | 0.01% | 1505 |
|
|
2017
Q2 | $4.15M | Buy |
32,200
+2,100
| +7% | +$253K | ﹤0.01% | 1681 |
|
|
2017
Q1 | $3.29M | Sell |
30,100
-12,600
| -30% | -$1.11M | ﹤0.01% | 1808 |
|
|
2016
Q4 | $3.15M | Buy |
42,700
+15,500
| +57% | +$1.26M | ﹤0.01% | 1803 |
|
|
2016
Q3 | $2.37M | Buy |
27,200
+2,500
| +10% | +$236K | ﹤0.01% | 1932 |
|
|
2016
Q2 | $2.13M | Buy |
24,700
+16,500
| +201% | +$1.43M | ﹤0.01% | 1892 |
|
|
2016
Q1 | $652K | Buy |
8,200
+1,200
| +17% | +$109K | ﹤0.01% | 2203 |
|
|
2015
Q4 | $881K | Buy |
7,000
+2,700
| +63% | +$326K | ﹤0.01% | 2025 |
|
|
2015
Q3 | $448K | Sell |
4,300
-2,800
| -39% | -$360K | ﹤0.01% | 2082 |
|
|
2015
Q2 | $877K | Buy |
7,100
+2,700
| +61% | +$340K | ﹤0.01% | 1999 |
|
|
2015
Q1 | $519K | Sell |
4,400
-2,100
| -32% | -$252K | ﹤0.01% | 1976 |
|
|
2014
Q4 | $772K | Buy |
6,500
+4,800
| +282% | +$541K | ﹤0.01% | 1886 |
|
|
2014
Q3 | $191K | Buy |
+1,700
| New | +$162K | ﹤0.01% | 2165 |
|
Other funds holding VRTX
VCM
VPM
Allianz Asset Management's VRTX Position: Q1 2026 in Review
Allianz Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 5.3% in Q1 2026, selling an estimated $903K and leaving 34,339 shares worth $15.3M. The position accounts for 0.02% of the portfolio, ranked #705.
Allianz Asset Management first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $340M in Q3 2018. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Allianz Asset Management held 34,339 shares of Vertex Pharmaceuticals worth $15.3M as of Q1 2026.
- Allianz Asset Management sold 1,937 Vertex Pharmaceuticals shares in Q1 2026, an estimated $903K.
- Vertex Pharmaceuticals made up 0.02% of Allianz Asset Management's portfolio in Q1 2026, its #705 holding.
- Allianz Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Allianz Asset Management's Vertex Pharmaceuticals position peaked at $340M in Q3 2018.
- 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.